🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07019896
Recruiting Not applicable

Minimal Vitrectomy Surgery for Epiretinal Membrane

NCT07019896 · tracked via the Priya Life Science China tracker
Sponsor
Peking Union Medical College Hospital
Phase
Not applicable
Started
2024-12-01
Last updated
2025-06-13

Condition(s) studied

Epiretinal MembraneMacular Edema (ME)Nuclear Cataract

Investigational drug(s) / intervention(s)

Minimal Vitrectomy SurgeryConventional Vitrectomy

Minimal Vitrectomy Surgery: The epiretinal membrane is peeled directly through the intact vitreous. Limited localized vitrectomy is selectively performed if pre-existing floaters or membrane fragments remain after peeling.

Conventional Vitrectomy: Standard pars plana vitrectomy is performed with posterior vitreous detachment induction and core vitreous removal prior to epiretinal membrane peeling.

Study summary

This multicenter randomized controlled trial evaluates Minimal Vitrectomy Surgery (MVS) versus conventional vitrectomy for idiopathic epiretinal membrane (ERM). The primary endpoints include visual acuity improvement and cataract progression after 12 months. MVS aims to minimize vitreous removal while ensuring complete membrane removal through adaptive limited vitrectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years. 2. Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging. 3. Clear ocular media allowing adequate fundus imaging. 4. Phakic eye. 5. Ability and willingness to provide written informed consent. Exclusion Criteria: 1. Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion). 2. Systemic conditions preventing safe surgery or follow-up. 3. History of prior ocular or periocular corticosteroid use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking Union Medical College Hospital Beijing Beijing Municipality Recruiting

More Peking Union Medical College Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07019896 on ClinicalTrials.gov ↗ ← All trials in China